Ester-C (Calcium Ascorbate) Oral Tablet
Ester-C is a calcium ascorbate formulation of vitamin C indicated for vitamin C supplementation, with standard dosing of 50-500 mg/day depending on clinical context, minimal contraindications, excellent safety profile, and few clinically significant drug interactions.
Indications
Ester-C (calcium ascorbate) is indicated for:
- Prevention and treatment of vitamin C deficiency (scurvy)
- Supplementation in chronic oxidative stress conditions: diabetes mellitus, heart failure, smoking, alcoholism, severe COPD, and chronic dialysis 1
- Malabsorption states including post-bariatric surgery 1
- General health maintenance in individuals with inadequate dietary intake
The 2022 ESPEN guidelines provide the most authoritative framework for vitamin C supplementation across clinical contexts 1.
Recommended Dosing
Standard Populations
Special Populations Requiring Higher Doses
- Chronic oxidative stress conditions (diabetes, heart failure, smoking, alcoholism, severe COPD, chronic dialysis): 200-500 mg/day 1
- Malabsorption states: 200-500 mg/day may be required 1
- Post-bariatric surgery: 200-500 mg/day 1
Critical Illness (Note: Requires IV Administration)
For completeness, critically ill patients require 2-3 g/day IV during acute inflammation, but this exceeds oral tablet capabilities 1, 2.
Formulation Considerations
Calcium ascorbate (Ester-C) may offer better gastrointestinal tolerance compared to regular ascorbic acid, particularly in acid-sensitive individuals. A 2006 study demonstrated significantly fewer epigastric adverse effects (37.5% vs 62.5%) and better tolerability ratings (72% "very good" vs 54%) with Ester-C compared to ascorbic acid 3. However, bioavailability differences remain debated, with one animal study suggesting enhanced potency 4 while a 2024 human study showed minimal differences at 250 mg but some immune benefits at 500 mg 5.
Contraindications
Absolute contraindications for high-dose vitamin C supplementation include:
- Renal insufficiency or chronic hemodialysis patients (selenium excretion concerns apply; vitamin C itself requires monitoring) 6
- Unusual forms of iron overload (hemochromatosis, thalassemia) - vitamin C enhances iron absorption 6
- Active oxalate stone formers - theoretical risk of calcium oxalate stone formation 6
- Known hypersensitivity to calcium ascorbate or any component
Important caveat: The FDA drug label evidence 7 pertains to estrogen products (DEPO-Estradiol), NOT Ester-C, and should be disregarded for this question.
Adverse Effects
Vitamin C, including calcium ascorbate formulations, demonstrates excellent safety at recommended doses:
Common (Dose-Dependent)
- Gastrointestinal effects: Nausea, diarrhea, abdominal cramping (typically at doses >1000 mg/day)
- Epigastric discomfort: Significantly reduced with Ester-C vs regular ascorbic acid 3
Theoretical Concerns (Largely Unfounded)
Extensive literature review demonstrates that in healthy individuals, gram doses do NOT induce 6:
- Renal calcium oxalate stones
- Systemic conditioning (rebound scurvy)
- Uricosuria
- Vitamin B12 destruction
- Mutagenicity
Monitoring Considerations
- Renal function: In patients with renal insufficiency
- Iron studies: In patients with iron overload disorders
- Urinary oxalate: In known stone formers
Drug Interactions
Vitamin C has minimal clinically significant drug interactions at standard supplementation doses:
Pharmacodynamic Interactions
- Enhanced iron absorption: Beneficial in iron deficiency; problematic in iron overload 6
- Potential interaction with anticoagulants: Theoretical only; not clinically significant at standard doses
- Chemotherapy agents: High-dose IV vitamin C (not oral tablets) may interact with certain chemotherapy; standard oral doses are safe 8, 9
Pharmacokinetic Considerations
Oral vitamin C absorption is tightly regulated by three mechanisms: intestinal absorption, tissue accumulation, and renal reabsorption 9. Even with high oral doses, plasma concentrations rarely exceed 250 μmol/L, limiting interaction potential 9.
Clinical Pearls
- Oral bioavailability is saturable: Doses above 500 mg provide diminishing returns for plasma concentration 9
- Divided dosing: For doses >500 mg/day, divide into 2-3 doses for better absorption
- Calcium content: Ester-C contains calcium; consider in patients requiring calcium restriction
- Inflammation affects interpretation: Plasma vitamin C levels decline rapidly with CRP >10 mg/L, making measurement unreliable during acute illness 1
- Clinical trial for suspected deficiency: 1 g/day for at least one week should not be delayed if scurvy is suspected 1